{"name":"Genetron Holdings","slug":"genetron","ticker":"GTH","exchange":"NASDAQ","domain":"genetronhealth.com","description":"Genetron Holdings (GTH) is a cancer genomics and diagnostics company focused on developing and commercializing innovative cancer diagnostic and therapeutic products. The company's top drugs include its flagship product, Genie, a next-generation sequencing (NGS) platform for cancer diagnosis and treatment. Genetron Holdings has established a strong presence in the cancer genomics and diagnostics market, with a growing portfolio of products and a commitment to advancing cancer research and treatment. As a leading player in the industry, Genetron Holdings is well-positioned to capitalize on the growing demand for cancer diagnostics and therapeutics.","hq":"Beijing, China","founded":2017,"employees":"~200","ceo":"Sizhen Wang","sector":"Cancer Genomics / Diagnostics","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$1.3B","metrics":{"revenue":95000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-03-15","type":"earnings","headline":"Genetron Holdings Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Genetron Holdings reported its fourth quarter and full year 2023 financial results, with revenue of $123.4 million and a net loss of $43.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-01","type":"deal","headline":"Genetron Holdings Enters into Strategic Partnership with Shanghai Municipal Government","summary":"Genetron Holdings entered into a strategic partnership with the Shanghai Municipal Government to accelerate the development and commercialization of its cancer diagnostic and therapeutic products in China.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOcWQtVHVXakFDQzZ6bUlSVWN0a3QtVUcxS3lHSkxvUUIyRTlucjd4X0h2RzlMZ3hyZ0NTMm9BWld6TG5IR3R0UVVKaVZLb1QxSE9TZWt0VGd6VjJ1YkstRG4xS3JBNDN3Y25hVUd2NHl1VFF5UkpsOVJLQk9hRjhTZUxhTDRmQy1BdDNUVTl5TFhSdmN3Q19McnVIZVlnb0hvc3FZRlR3bXhfMG03X2ozNEVxVXNVcy10UUw4R3RzODdWUQ?oc=5","date":"2021-06-07","type":"pipeline","source":"BioPharma APAC","summary":"Genetron Health ,Siemens Healthineers to Promote Precision Oncology for Lung Cancer - BioPharma APAC","headline":"Genetron Health ,Siemens Healthineers to Promote Precision Oncology for Lung Cancer","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Illumina","Thermo Fisher Scientific","Qiagen"],"therapeuticFocus":["Cancer Genomics","Cancer Diagnostics"],"financials":null,"yahoo":null}